- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06183476
Circadian Amplification in Diabetic Retinopathy
December 13, 2023 updated by: University of Illinois at Chicago
This study will test the effects of a 6-week comprehensive circadian optimization intervention Amplify-RHYTHM in patients with diabetic retinopathy.
The outcomes of interest are objective and subjective sleep parameters, evening salivary cortisol and melatonin levels, and glucose parameters from continuous glucose monitoring
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study will test the effects of a 6-week comprehensive circadian optimization intervention Amplify-RHYTHM in patients with diabetic retinopathy.
The two main components of the intervention are timed light exposure and weekly remote coaching session by psychologist to optimize circadian and sleep behaviors.
The outcomes of interest are objective and subjective sleep parameters, evening salivary cortisol and melatonin levels, and glucose parameters from continuous glucose monitoring
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- type 2 diabetes
- a history of at least moderate non-proliferative diabetic retinopathy
- would like to improve sleep
- own a smartphone compatible with fitbit.
Exclusion Criteria:
- Use of melatonin
- Use of antipsychotics
- Use of more than one antidepressant. The dose of which needs to be stable for 6 weeks.
- illicit drug use
- night shift work or travel beyond 2 time zones in the month before enrollment
- end stage renal disease requiring renal replacement therapy
- history of stroke or transient ischemic attacks
- history of dementia or memory impairment
- uncontrolled congestive heart failure or recent hospitalization for cardiac condition (6 months)
- chronic obstructive pulmonary disease requiring oxygen
- severe chronic liver disease such as cirrhosis
- ongoing treatment for major medical problems such as cancer
- history of severe hypoglycemia defined as hypoglycemic episodes requiring assistance from others within the past six months.
- Regular use of sedatives and hypnotics (>2 times/ month).
- clinically significant epiretinal membranes, clinically significant lens opacities, or cystoid macular edema, iris neovascularization, iris atrophy, or an asymmetrically shaped pupil, nuclear sclerotic, posterior subcapsular, or cortical lens opacities greater than 2+, a history of pan-retinal photocoagulation.
- Significant depressive symptoms as assessed by PHQ-8 questionnaire (score >14)
- No health insurance coverage
- History of untreated severe OSA.
- Uncontrolled hypertension (blood pressure ≥ 160/100 mmHg),
- Uncontrolled diabetes (A1C ≥ 11%)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Amplify-RHYTHM will consist of two main components: 1) timed light exposure, 2) weekly remote coaching session.
|
Amplify-RHYTHM will have two main components: 1) timed light exposure (increase light in the morning, blue light reduction in the evening and eye masks at night), 2) weekly remote coaching session by psychologist to optimize circadian and sleep behaviors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep
Time Frame: baseline and 6-week
|
Objective and Subjective Sleep Parameters
|
baseline and 6-week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Salivary melatonin and cortisol
Time Frame: baseline and 6-week
|
Evening salivary melatonin and cortisol
|
baseline and 6-week
|
Glucose levels
Time Frame: baseline and 6-week
|
Glucose from continuous glucose monitoring
|
baseline and 6-week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 1, 2024
Primary Completion (Estimated)
February 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
December 13, 2023
First Submitted That Met QC Criteria
December 13, 2023
First Posted (Actual)
December 27, 2023
Study Record Updates
Last Update Posted (Actual)
December 27, 2023
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-1387
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on Amplify-RHYTHM
-
Tan Tock Seng HospitalNot yet recruiting
-
Laboratório de Pesquisa em Lazer e Atividade FísicaUnknownQuality of Life | Parkinson Disease | Sleep Disorder | Gait Disorders, Neurologic | Mobility Limitation
-
University Hospital, ToulouseNot yet recruiting
-
Assaf-Harofeh Medical CenterHadassah Medical Organization; Western University, CanadaNot yet recruitingADHD | Memory Impairment | T1DM | Sleep Disorders, Circadian Rhythm
-
Catholic University of the Sacred HeartFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; ASST Fatebenefratelli... and other collaboratorsRecruitingDevelopmental DyslexiaItaly
-
University Hospital, MontpellierUniversité Montpellier; Laboratory Parole et Langage UMR 7309; Laboratory EUROMOV...Suspended
-
Ziekenhuis Oost-LimburgCompletedAtrial FibrillationBelgium
-
University of MichiganNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingStuttering | Stuttering, ChildhoodUnited States
-
Duke UniversityCompletedDepression | Cancer | Anxiety | Chronic Fatigue SyndromeUnited States
-
University Hospital Inselspital, BerneNational Academy of Medical Sciences, NepalRecruitingArrhythmias, Cardiac | Bradycardia | Tachycardia, Ventricular | Tachycardia, SupraventricularNepal